Fertin, officially known as Fertin Pharma A/S, is a leading player in the pharmaceutical and healthcare industry, headquartered in Denmark (DK). Founded in 2006, the company has established itself as a pioneer in the development of innovative oral delivery systems, particularly in the field of nicotine replacement therapy and other consumer health products. With a strong presence in Europe and North America, Fertin focuses on creating unique solutions that enhance the efficacy and user experience of medicinal products. Their core offerings include advanced chewing gum and lozenge formulations, which are distinguished by their high bioavailability and consumer-friendly designs. Fertin's commitment to quality and innovation has positioned it as a trusted partner for global brands, earning recognition for its contributions to the industry and its ability to adapt to evolving market demands.
How does Fertin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Fertin's score of 68 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Fertin Pharma A/S reported total carbon emissions of approximately 43.7 million kg CO2e, comprising 3,654,000 kg CO2e from Scope 1, 1,538,000 kg CO2e from Scope 2 (market-based), and 36,673,000 kg CO2e from Scope 3 emissions. This reflects a slight decrease from 2023, where total emissions were approximately 43.5 million kg CO2e, with Scope 1 emissions at 4,742,000 kg CO2e, Scope 2 (market-based) at 1,865,000 kg CO2e, and Scope 3 at 34,261,000 kg CO2e. Fertin's emissions data is cascaded from its parent company, Philip Morris International Inc., indicating a corporate commitment to sustainability. However, there are currently no specific reduction targets or climate pledges outlined in their reports. The company is actively working within the framework of its parent organisation's sustainability initiatives, which may include broader industry standards and practices. Fertin Pharma's headquarters is located in Denmark (DK), and it continues to align its operations with global climate commitments, although specific reduction initiatives have not been detailed in the available data.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fertin has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.